Lurker Nancy 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Dec 1, 2025
Insider Transaction Report
Form 4
Lurker Nancy
Director
Transactions
- Sale
Common Stock
2025-11-26$14.95/sh−200$2,990→ 216,347 total - Sale
Common Stock
2025-11-28$14.95/sh−500$7,475→ 215,847 total
Holdings
- 126,889(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price as these shares were sold in multiple transactions. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.